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Abstract
Background: Microbial aetiology of intensive care unit (ICU)-acquired pneumonia (ICUAP) determines antibiotic
treatment and outcomes. The impact of polymicrobial ICUAP is not extensively known. We therefore investigated
the characteristics and outcomes of polymicrobial aetiology of ICUAP.
Method: Patients with ICUAP confirmed microbiologically were prospectively compared according to identification
of 1 (monomicrobial) or more (polymicrobial) potentially-pathogenic microorganisms. Microbes usually considered
as non-pathogenic were not considered for the etiologic diagnosis. We assessed clinical characteristics,
microbiology, inflammatory biomarkers and outcome variables.
Results: Among 441 consecutive patients with ICUAP, 256 (58 %) had microbiologic confirmation, and 41 (16 %) of
them polymicrobial pneumonia. Methicillin-sensitive Staphylococcus aureus, Haemophilus influenzae, and several
Enterobacteriaceae were more frequent in polymicrobial pneumonia. Multi-drug and extensive-drug resistance
was similarly frequent in both groups. Compared with monomicrobial, patients with polymicrobial pneumonia
had less frequently chronic heart disease (6, 15 % vs. 71, 33 %, p = 0.019), and more frequently pleural effusion
(18, 50 %, vs. 54, 25 %, p = 0.008), without any other significant difference. Appropriate empiric antimicrobial
treatment was similarly frequent in the monomicrobial (185, 86 %) and the polymicrobial group (39, 95 %), as
were the initial response to the empiric treatment, length of stay and mortality. Systemic inflammatory response
was similar comparing monomicrobial with polymicrobial ICUAP.
Conclusion: The aetiology of ICUAP confirmed microbiologically was polymicrobial in 16 % cases. Pleural effusion and
absence of chronic heart disease are associated with polymicrobial pneumonia. When empiric treatment is frequently
appropriate, polymicrobial aetiology does not influence the outcome of ICUAP.
Keywords: Hospital-acquired pneumonia, ICU-acquired pneumonia, Ventilator-acquired pneumonia, Polymicrobial
pneumonia
Background
Intensive care unit (ICU)-acquired pneumonia (ICUAP)
is the leading infection in critically-ill patients, account-
ing for prolonged mechanical ventilation and length of
stay, and poor outcome [1–4]. The use of inappropriate
initial antibiotic therapy is a major determinant of
mortality in patients with ICUAP [5], emphasizing the
importance of a timely and accurate therapy for this in-
fection [6]. For this reason, it is often necessary to use a
combination of broad-spectrum empiric antibiotics, par-
ticularly in patients who are at risk for difficult-to-treat
bacteria [7, 8]. Recent investigations have shown that
multi-drug-resistant (MDR) or high-risk pathogens have
been isolated in around half of patients with an episode
of ventilator-associated pneumonia (VAP) or ICUAP
confirmed microbiologically [9, 10].
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ICUAP, and particularly VAP, can be caused by more
than one microbial pathogen. Multiple etiologic pathogens
are potentially an additional challenge for achieving
appropriate antimicrobial treatment in these patients. A
previous study reported a 48 % rate of polymicrobial eti-
ology in episodes of VAP with microbiologic confirmation
[11]. These authors concluded that the epidemiology and
outcomes of patients with monomicrobial and polymicro-
bial VAP did not differ significantly. However, in this
study, a substantial proportion of episodes classified as
polymicrobial VAP had positive isolation of bacteria usu-
ally considered as non-pathogenic microorganisms. More-
over, between 15 % and 73 % patients with an episode of
ICUAP are not previously intubated [2, 12, 13], namely
non-ventilator ICUAP (NV-ICUAP).
To our knowledge, no previous studies have comprehen-
sively assessed polymicrobial ICUAP strictly considering
the identification of potentially pathogenic microorganisms
(PPM). We have recently shown that positive microbiology
is associated with worse outcomes in patients with clinical
diagnosis of ICUAP [14]. Therefore, whether patients with
polymicrobial etiology of ICUAP have different characteris-
tics and outcomes to those with monomicrobial etiology is
unknown. We therefore investigated the incidence, charac-
teristics, risk factors, systemic inflammatory response and




The study was conducted between October 2004 and
September 2013 in six medical and surgical ICUs, com-
prising 45 beds, at Hospital Clinic, Barcelona, Spain, an
800-bed university hospital. The investigators made daily
rounds in each ICU. Patients older than 18 years, admit-
ted to these ICUs for 48 h or more, with clinical diagnosis
of ICUAP were consecutively enrolled in the study, and
this being only the first episode, were analyzed. Exclusion
criteria were: 1) severe immune suppression (neutropenia
after chemotherapy or hematopoietic transplant, drug-
induced immune suppression in solid-organ transplant or
cytotoxic therapy, and patients with human immunodefi-
ciency virus) and 2) absence of microbiologic confirm-
ation. The institution’s Internal Review Board approved
the study (Comite Etic d’Investigacio Clinica, registry
number 2009/5427) and written informed consent was
obtained from patients or their next of kin.
Definition of pneumonia, microbiologic processing, and
antimicrobial treatment
Clinical diagnosis of ICUAP was based on clinical cri-
teria: new or progressive radiological pulmonary infil-
trate together with at least two of the following:
temperature >38 °C or <36 °C, leukocytosis >12,000/
mm3 or leukopenia <4,000/mm3, and purulent respira-
tory secretions [1, 15, 16]. Non-ventilated ICUAP was
defined when patients acquired pneumonia after more
than 48 h of ICU admission and without previous mech-
anical ventilation [2]. We considered VAP in patients
with previous invasive mechanical ventilation for 48 h or
more. Early-onset pneumonia was defined as occurring
within the first 4 days of hospitalization [1].
The microbiologic evaluation included the collection
of at least one lower respiratory tract sample: sputum
in non-ventilated patients, tracheobronchial aspirates
(TBAS) in intubated patients, and/or bronchoscopic
[17] or blind bronchoalveolar lavage (BAL) [18], whenever
possible, within the first 24 h of inclusion [19]. Broncho-
scopic BAL and blind BAL were performed as previously
described [19].
The same sampling method was performed on the
third day if clinically indicated. Blood cultures and cul-
tures from pleural fluid, if puncture was indicated, were
also taken. Urinary antigens of Legionella pneumophila
and Streptococcus pneumoniae were systematically
collected. Microbiologic confirmation of pneumonia was
defined by the presence of at least one PPM in respira-
tory samples above predefined thresholds (BAL >104,
sputum or TBAS >105 colony-forming units/mL,
respectively), in pleural fluid or in blood cultures if an
alternative cause of bacteremia was ruled out [20, 21].
Drug resistance of pathogens was defined according to
a recent report [22]. MDR pathogens were defined as
acquired non-susceptibility to at least one agent in three
or more antimicrobial categories. Extensive drug resist-
ance (XDR) was defined as non-susceptibility to at least
one agent in all but two or fewer antimicrobial categor-
ies (i.e., bacterial isolates remain susceptible to only one
or two categories). Pan drug resistance (PDR) was
defined as non-susceptibility to all agents in all anti-
microbial categories. We considered methicillin-resistant
Staphylococcus aureus (MRSA), and Enterobacteriaceae
producing extended-spectrum β-lactamase as MDR
pathogens [9].
Monomicrobial and polymicrobial pneumonia were
defined when one and more than one PPM, respectively,
were identified as etiologic agents at onset of pneumo-
nia. Isolation of Candida spp, Streptococcus viridans,
Staphylococcus epidermidis, Neisseria spp, Enterococcus
spp, and Corynebacterium spp in lower respiratory tract
samples were not considered etiologic agents.
The initial empiric antimicrobial treatment was
administered according to local adaptation of the American
Thoracic Society/Infectious Disease Society of America
guidelines [1], based on the most frequently isolated PPM
and their patterns of antimicrobial sensitivity in our institu-
tion, and subsequently revised according to the microbio-
logic results. The empirical antimicrobial treatment was
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considered appropriate when the isolated pathogens were
susceptible in vitro to at least one of the antimicrobials ad-
ministered at an adequate dose [8].
We assessed the initial response to treatment after 72
to 96 h of antimicrobial treatment, as previously de-
scribed [23, 24]. Non-response was considered when at
least one of the following criteria were present: 1) no
improvement of the arterial O2 tension to inspired O2
fraction ratio or need for intubation because of pneumo-
nia (defined as need for intubation after 24 h from the
beginning of antibiotics); 2) persistence of fever
(temperature ≥38 °C) or hypothermia (<35.5 °C) together
with purulent respiratory secretions; 3) increase in the
pulmonary infiltrates on chest radiograph ≥50 %; or 4)
occurrence of septic shock or multiple organ dysfunction
syndrome, defined as three or more organ system
failures not present on day 1.
Assessment of systemic inflammatory response
We evaluated the serum levels of interleukin (IL)-6, IL-8,
tumor necrosis factor-alpha (TNF-alpha), C-reactive pro-
tein, procalcitonin and mid-regional pro-adrenomedullin
within the first 24 h after the diagnosis of pneumonia. All
methods of these analyses have been recently described in
detail [25, 26].
Data collection
All relevant data were collected at admission and at onset
of pneumonia from the medical records and bedside flow
charts, including laboratory, radiologic and microbiologic
information. We calculated the acute physiology and
chronic health evaluation (APACHE)-II score [27] and the
simplified acute physiology score (SAPS)-II [28] on ICU
admission. The simplified clinical pulmonary infectious
score (CPIS) [29] and the sepsis-related organ failure
assessment (SOFA) [30] scores were also evaluated on
ICU admission and up to 9 days after the onset of pneu-
monia. Septic shock [31] and acute respiratory distress
syndrome (ARDS) [32] were defined according to previ-
ously described criteria. Patients were followed until death
or up to 90 days after the diagnosis of pneumonia.
Outcome variables
The outcomes of patients with monomicrobial pneumonia
were compared to those with polymicrobial pneumonia.
The primary outcome variable was mortality at 90 days
after the diagnosis of ICUAP. Secondary outcomes in-
cluded initial non-response to treatment, length of ICU
and hospital stay, ventilator-free days at day 28 [33], and
mortality at 28 days.
Statistical analysis
Categorical and continuous data are presented as number
(percentage) and as mean ± SD (or median (inter-quartile
range)), respectively. Categorical variables were compared
with the chi square (χ2) test or the Fisher exact test.
Quantitative continuous variables were compared using
the t test or the Mann–Whitney test for normally and
non-normally distributed variables, respectively. Survival
curves for patients with monomicrobial and polymicrobial
pneumonia were obtained using the Kaplan-Meier method
and compared using the log-rank test.
The association between polymicrobial or monomicro-
bial etiology and patients’ outcomes was adjusted for
variables potentially related to mortality, such as age,
APACHE-II and SAPS scores at ICU admission, SOFA
score, CPIS and arterial partial pressure of oxygen/in-
spired oxygen fraction (PaO2/FiO2) ratio at onset of pneu-
monia, VAP or NV-ICUAP, and unilateral or bilateral
chest x-ray infiltrates. We used Cox proportional hazard
regression analysis for 28-day and 90-day mortality.
All reported P values are two-sided and not adjusted for
multiple comparisons. A P value <0.05 was considered
significant. All statistical analyses were performed using
IBM SPSS Statistics Version 20 (Armonk, NY, USA).
Results
Patients’ characteristics
We prospectively identified 441 consecutive patients with
ICUAP; 185 (42 %) were excluded because a positive
microbiological diagnosis could not be made. Therefore,
we included 256 patients: 215 (84 %) with monomicrobial,
and 41 (16 %) with polymicrobial ICUAP (Fig. 1).
The characteristics of patients at ICU admission and
at onset of pneumonia are summarized in Tables 1 and
2. The rate of chronic heart disease was lower, and the
rate of pleural effusion was higher, in patients with
polymicrobial, compared to monomicrobial pneumonia.
No other significant differences were found between the
two groups in the remaining baseline characteristics, co-
morbidities, reasons for ICU admission, disease severity,
and laboratory variables at the onset of pneumonia.
Microbiologic assessment
The proportions of lower respiratory tract samples proc-
essed for microbiology were similar in the two groups
(Table 3). However, blood and pleural fluid culture were
performed more often in patients with polymicrobial
pneumonia, in case of pleural fluid, owing to the higher
incidence of pleural effusion in this group.
There were 2 patients (5 %) in the polymicrobial pneu-
monia group with methicillin-sensitive Staphylococcus
aureus (MSSA) isolated in pleural fluid. In the monomi-
crobial pneumonia group, 8 patients (4 %) had positive
pleural fluid cultures: MSSA and Pseudomonas aerugi-
nosa in 3 patients, and MRSA in 2 patients.
There were 5 patients (12 %) in the polymicrobial
pneumonia group with positive blood cultures: Serratia
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Fig. 1 Trial profile of included and excluded patients. ICU intensive care unit, VAP ventilator-associated pneumonia, ICUAP ICU-acquired pneumonia






Age, years 63 ± 16 60 ± 17 0.34
Sex, male, n (%) 155 (72) 31 (76) 0.64
APACHE-II score 17 ± 6 18 ± 6 0.52
SAPS-II score 41 ± 15 42 ± 13 0.66
SOFA score 7.2 ± 3.1 7.8 ± 3.3 0.28
Current or former smokers, n (%) 113 (53) 20 (49) 0.66
Current or former alcohol abuse, n (%) 57 (27) 10 (24) 0.77
Co-morbidities, n (%)
Diabetes mellitus 47 (22) 10 (24) 0.72
Chronic renal failure 17 (8) 2 (5) 0.50
Solid cancer 41 (19) 3 (7) 0.068
Chronic heart disorders 71 (33) 6 (15) 0.019
Chronic lung disease 74 (34) 10 (24) 0.21
Chronic liver disease 36 (17) 8 (20) 0.67
Recent surgery, n (%) 97 (45) 15 (37) 0.31
Tracheostomy at admission, n (%) 24 (11) 4 (10) 0.78
Main causes of ICU admission, n (%)
Postoperative 38 (18) 4 (10) 0.31
Hypoxemic respiratory failure 37 (17) 7 (17) 0.85
Decreased consciousness 31 (14) 8 (20) 0.56
Hypercapnic respiratory failure 26 (12) 2 (5) 0.28
Cardiac arrest 15 (7) 4 (10) 0.77
Septic shock 17 (8) 3 (7) 0.85
Multiple trauma 18 (8) 6 (15) 0.34
Non-surgical abdominal disease 10 (5) 3 (7) 0.75
Previous antibiotics in the ICU, n (%) 163 (76) 31 (76) 0.98
Previous cardiopulmonary resuscitation, n (%) 23 (11) 4 (10) 0.86
APACHE acute physiology and chronic health evaluation; SAPS simplified acute physiology score; SOFA sepsis-related organ failure assessment; ICU intensive
care unit
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spp. in 2 patients, and MSSA, Escherichia coli, and
Fusobacterium spp. in 1 patient. The pathogens
concomitantly isolated in respiratory samples from these
patients with bacteremia were: Serratia spp. (Morganella
morganii and MSSA), MSSA (S. pneumoniae), E. coli
(MSSA), and Fusobacterium spp. (E. coli). In the mono-
microbial pneumonia group, 18 patients (8 %) had posi-
tive blood cultures: P. aeruginosa in 4 patients, MRSA
and E. coli in 3 patients, MSSA and Klebsiella spp. in 2 pa-
tients, and Stenotrophomonas maltophilia, Citrobacter spp.,
Bacteroides fragilis and Proteus mirabilis in 1 patients.
The etiologic diagnosis of pneumonia is shown in
Table 4. All patients with polymicrobial pneumonia
had two different pathogens identified, except two
who had three different pathogens identified (Table 5).
The most frequently isolated pathogens were P.
aeruginosa, Enterobacteriaceae, and MSSA. Several
bacteria, such as MSSA, Haemophilus influenzae,
Klebsiella spp., E. coli, Enterobacter spp., Citrobacter
spp., and Serratia spp., were more frequently isolated
in patients with polymicrobial pneumonia. The
remaining pathogens were isolated at similar rates in
both groups. These findings were similar when we
analyzed patients with VAP and non-ventilator
ICUAP separately.
The proportion of patients with MDR and XDR patho-
gens isolated were similar in both groups (Table 4). There
were no patients with PDR microorganisms. Patients
treated with antibiotics before the onset of ICUAP more
frequently had MDR or XDR pathogens than those not
treated previously with antibiotics (59 (30 %) vs. 9 (15 %),
respectively, p = 0.014). A new microbiologic evaluation
was done on the third day of evolution in 169 patients
(79 %) and 33 patients (80 %) from the monomicrobial and
polymicrobial groups, respectively. The microbiologic
evolution is shown in Table 4.






Ventilator-associated pneumonia, n (%) 147 (68) 32 (78) 0.22
Non-ventilator-ICUAP, n (%) 68 (32) 9 (22)
Early-onset pneumonia, n (%) 55 (26) 14 (34) 0.27
Late-onset pneumonia, n (%) 159 (74) 27 (66)
ICU stay before pneumonia, days 7 ± 8 8 ± 9 0.79
Hospital stay before pneumonia, days 12 ± 13 10 ± 9 0.26
SOFA score 7.5 ± 3.4 7.9 ± 3.0 0.51
CPIS day 1 6.4 ± 1.5 6.9 ± 1.5 0.026
Previous use of corticosteroids, n (%) 81 (38) 20 (50) 0.14
Previous airway colonization, n (%) 87 (41) 12 (29) 0.18
ARDS criteria, n (%) 22 (10) 7 (18) 0.16
Pleural effusion, n (%) 52 (25) 20 (49) 0.002
Shock at onset of pneumonia, n (%) 101 (47) 19 (46) 0.94
Serum creatinine, mg/Dl 1.25 ± 1.04 1.15 ± 0.90 0.57
Blood hemoglobin, g/L 10.5 ± 1.7 10.9 ± 1.9 0.14
White blood cell count, L−9 14,068 ± 7,282 12,510 ± 4,893 0.19
PaO2/FiO2, mmHg 210 ± 82 202 ± 80 0.56
ICU intensive care uni, ICUAP ICU-acquired pneumonia, SOFA sepsis-related organ failure assessment, CPIS clinical pulmonary infection score, ARDS acute respiratory
distress syndrome, PaO2/FiO2 ratio of arterial oxygen tension to inspired oxygen fraction






Any lower respiratory tract sample, n (%) 213 (99) 41 (100) 0.54
Tracheal aspirate or sputum, n (%)a 202 (94) 38 (93) 0.76
Bronchoalveolar lavage, n (%) 41 (19) 9 (22) 0.68
Pleural fluid culture, n (%) 18 (8) 9 (22) 0.009
Blood culture, n (%) 143 (67) 34 (83) 0.037
aSputum or tracheal aspirates were obtained depending on whether or not patients were intubated at onset of pneumonia. In some patients, a sample of both
sputum and tracheal aspirate were processed for culture
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Table 4 Etiologic diagnosis of pneumonia






Methicillin-sensitive Staphylococcus aureus 39 (18) 14 (34) 0.037
Methicillin-resistant Staphylococcus aureus 18 (8) 3 (7) 0.94
Streptococcus pneumoniae 10 (5) 3 (7) 0.75
Gram-negative bacteria
Enterobacteriaceae
Klebsiella spp. 14 (7) 9 (22) 0.005
Escherichia coli 9 (4) 10 (24) <0.001
Proteus spp. 3 (1) 3 (7) 0.087
Enterobacter spp. 9 (4) 6 (15) 0.025
Citrobacter spp. 2 (1) 3 (7) 0.039
Serratia spp. 9 (4) 6 (15) 0.025
Morganella morganii 1 (0.5) 1 (2.4) 0.73
Haemophilus influenza 6 (3) 5 (12) 0.023
Non-fermenting Gram-negative bacilli
Stenotrophomonas maltophilia 12 (6) 4 (10) 0.51
Pseudomonas aeruginosa 74 (34) 12 (29) 0.65
Acinetobacter spp. 0 1 (2.4) 0.38
Moraxella catarrhalis 2 (0.9) 1 (2.4) 0.98
Fusobacterium spp. 0 1 (2.4) 0.38
Bacteroides fragilis 1 (0.5) 0 0.36
Fungi
Aspergillus spp. 6 (3) 2 (5) 0.84
Bacteremia 18 (8) 5 (12) 0.63
Patients with drug-resistant pathogens: 0.61
MDR pathogens 38 (18) 9 (22)
XDR pathogens 19 (9) 2 (5)
MDR pathogens isolateda:
Methicillin-resistant S. aureus 18 3
Non-fermenting Gram-negative bacilli 12 1
Enterobacteriaceae 8 7
XDR pathogens isolated:
Non-fermenting Gram-negative bacilli 18 2
Enterobacteriaceae 1 0
Microbiologic evolution on day 3:
Persistence of 2 pathogens from day 1 - 5 (12)
Persistence of 1 pathogen from day 1 74 (34) 13 (32)
Persistence + new pathogen isolated 12 (6) 0 (0)
Eradication but new pathogen isolated 12 (6) 1 (2)
Eradication of initial pathogen 71 (33) 14 (34)
Microbiologic evaluation on day 3 not done 46 (21) 8 (20)
aIn two patients with polymicrobial pneumonia, both pathogens were multi-drug-resistant (MDR). XDR extensive-drug-resistant
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Assessment of systemic inflammatory response
The serum levels of all inflammatory biomarkers were
similar in patients from the two groups (Table 6).
Outcome variables
The appropriateness of the empirical antimicrobial treat-
ment, the initial non-response to treatment, the length of
stay, the ventilator-free days, and mortality at 28 and
90 days were similar in both groups (Table 7 and Fig. 2).
Mortality of patients adjusted for initial non-response to
treatment did not differ between groups (28 days: p = 0.71;
90 days: p = 0.49).
The most frequent cause of death was shock-multiple
organ failure. Even when adjusted for variables poten-
tially related to mortality, the polymicrobial etiology of
ICUAP was not associated with 28-day mortality
(adjusted hazard ratio 0.86, 95 % confidence interval
0.44–1.58, p = 0.65) or 90-day mortality (adjusted hazard
ratio 1.16, 95 % confidence interval 0.57–2.39, p = 0.69).
Discussion
Polymicrobial etiology accounted for 16 % cases of ICUAP
with positive microbiology. Except for less frequent
chronic heart disease and more frequent pleural effusion
in polymicrobial pneumonia, there were no other signifi-
cant differences between patients with monomicrobial
and polymicrobial pneumonia in their baseline character-
istics, inflammatory response or outcomes.
Information about the polymicrobial etiology of ICUAP
is limited. The only study that specifically addressed this
issue in VAP, published in 2002 [11], found a substantially
higher proportion of polymicrobial etiology (48 %)
compared to the present one. Unlike our study, those
authors included some bacteria that are considered non-
pathogenic for the lung in non-immunosuppressed pa-
tients, such as several Streptococcus species, Neisseria spp,
Enterococcus spp, and coagulase-negative Staphylococci.
Indeed, a substantial proportion of microbial isolates
reported in polymicrobial VAP in that study (42 %) repre-
sented these types of microbes [11]. Similarly, previous
observational studies reported rates of polymicrobial eti-
ology of VAP that ranged between 28 % and 50 % when
PPMs and non-pathogenic microbes were analyszed
[34–37]. Having included non-pathogenic microbes
would have increased the rate of polymicrobial pneumonia
to 30 % in our population. Conversely, we report in our
study that 16 % of patients with ICUAP had polymicrobial
etiology when we restricted the analysis to PPMs. A previ-
ous study that used the same criteria reported a similar
rate (10 %) for VAP of polymicrobial etiology [38].
A relevant issue in the polymicrobial etiology of
ICUAP is the potential prognostic implications. For that
reason, finding predictors of polymicrobial pneumonia
Table 5 Combinations of pathogens according to microbial
groups in patients with polymicrobial pneumonia
Pathogens Number
Patients with 3 pathogens identified
Enterobacteriaceae +MSSA + non-fermenting GNB 1
Enterobacteriaceae +MSSA + H. influenzae 1
Patients with 2 pathogens identified
2 Enterobacteriaceae 9
Enterobacteriaceae +MSSA 6
Enterobacteriaceae + non-fermenting GNB 6
2 non-fermenting GNB 3
Enterobacteriaceae + H. influenzae 2
Enterobacteriaceae +MRSA 2
MSSA + S. pneumoniae 2
MSSA + non-fermenting GNB 2
Enterobacteriaceae +M. catarrhalis 1
Enterobacteriaceae + Fusobacterium spp 1
MSSA + H. influenza 1
MSSA + Aspergillus spp. 1
Non-fermenting GNB + Aspergillus spp. 1
Non-fermenting GNB +MRSA 1
S. pneumoniae + H. influenzae 1
MSSA methicillin-sensitive Staphylococcus aureus, GNB Gram-negative bacilli,
MRSA methicillin-resistant Staphylococcus aureus






C-reactive protein, mg/dL 206 13 (7;22) 36 13 (4;25) 0.75
IL-6 day 1, pg/mL 107 157 (49:462) 19 92 (34;213) 0.19
IL-8 day 1, pg/mL 107 99 (59;209) 19 69 (55;161) 0.33
TNF-alpha day 1, pg/mL 107 8 (5;16) 19 7 (3;10) 0.30
Procalcitonin day 1, ng/mL 108 0.48 (0.15;1.57) 20 0.44 (0.06;1.72) 0.53
MR-proADM day 1, nmol/L 114 1.35 (0.55;2.28) 20 0.60 (0.25;2.02) 0.13
Reported values are median (interquartile range). aNumber of patients with samples processed for each inflammatory biomarker in each group. IL interleukin, MR-proADM
mid-regional pro-adrenomedullin, TNF tumor necrosis factor
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could hypothetically be of potential interest. However, in
a clinical setting of highly appropriate initial antibiotic
treatment, as reported in the present study for both
groups, all the outcomes, including length of stay,
ventilator-free days and mortality, were similar in the
two groups. Indeed, in our study the numbers of patients
with MDR or XDR pathogens in our study did not differ
with pneumonia of polymicrobial etiology. In addition,
when patients were clustered into non-ventilated ICUAP
and VAP, there were also no statistically significant
differences in these outcomes.
In our study, the only variables associated with poly-
microbial etiology were absence of chronic heart disease
and prior hospital admission, and the presence of pleural
effusion, which was twice as high in the polymicrobial
group. We have previously reported that patients with
clinical diagnosis of both community-acquired pneumo-
nia and ICUAP and negative microbiology more fre-
quently have chronic heart disease [14, 39]. Both studies
suggested that some of these cases might also represent,
at least in part, fluid overload due to congestive heart
failure added to the underlying inflammatory process
potentially mimicking pneumonia. Similarly, underlying
chronic heart disease might hypothetically have contrib-
uted to the development of pulmonary congestion in
patients with presumably lower bacterial burden, such as
those with pneumonia of monomicrobial etiology.
We do not have a clear explanation for the association
between a higher rate of pleural effusion and polymicro-
bial pneumonia. The isolation of MSSA in pleural fluid
culture from two patients was not sufficiently decisive to
allocate them to the polymicrobial pneumonia group; in
one patient, this pathogen was concomitantly identified
in blood and tracheal aspirate cultures, while in the
other, both H. influenzae and Klebsiella spp were
isolated in a tracheal aspirate culture. The association be-
tween pleural effusion and ICUAP of polymicrobial eti-
ology needs to be confirmed in future prospective studies.
Neither prior antibiotic treatment nor late-onset pneu-
monia, as in the previous French study [11], were pre-
dictors of polymicrobial pneumonia in our study.
However, prior antibiotic treatment was associated with
the presence of MDR or XDR pathogens in our study. In
addition we found no association between the severity of
presentation and polymicrobial etiology. This finding
complements a previous study in 343 patients with






Appropriate empiric treatment, n (%) 185 (86) 39 (95) 0.11
Initial non-response to treatment, n (%) 115 (54) 28 (68) 0.080
ICU stay, days 23 ± 19 25 ± 20 0.47
Hospital stay, days 44 ± 34 43 ± 31 0.98
Ventilator-free days at day 28 11 (0;23) 0 (0;21) 0.26
Cause of death within 90 days, n (%) 0.26
Shock-multiple organ failure 65 (70) 9 (56)
Refractory hypoxemia 11 (12) 2 (13)
Order do-not-resuscitate 6 (7) 0
Brain anoxia 8 (9) 4 (25)
Other 2 (2) 1 (6)
ICU intensive care unit
Fig. 2 Kaplan-Meier survival curves at 28 and 90 days in the study cohort survivors in patients with monomicrobial and polymicrobial pneumonia
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ICUAP that concluded that severity of illness seems not
to affect etiology [9].
We also found no differences in the serum levels of
any inflammatory biomarkers that we measured at the
onset of pneumonia. In relation to the etiology of
ICUAP, we have recently reported that inflammatory
biomarkers were unable to differentiate between patients
with positive and negative microbiology [14], or patients
with or without MDR pathogens [9]. All these studies
confirm that inflammatory biomarkers are not useful in
predicting the etiology of ICUAP.
The main strengths of our study are the prospective
design, the detailed description of microbiology in
ICUAP, the inclusion of both VAP and non-ventilator
ICUAP, the exclusion of non-potentially pathogenic mi-
croorganisms from the analysis, the assessment of sev-
eral inflammatory biomarkers, and the follow up of
patients up to 90 days. However, in our study we ex-
cluded immunosuppressed patients. Consequently, we
cannot extrapolate our results to this population.
This study has some limitations. First, it was conducted
in a single center, so the extrapolation of these findings to
other settings must be done cautiously. Second, we did
not use molecular microbiological techniques that are po-
tentially more sensitive. However, the experience of using
these techniques in ICUAP, and in non-ventilator ICUAP
and VAP, is still scarce. Third, the sample size of our study
is not enough large to make a robust analysis of all related
questions; when comparing several characteristics be-
tween the two groups of patients the current study was
underpowered. It is important to outline that this is a
non-interventional study and our purpose was only to de-
scribe clinical findings. Fourth, there were no adjustments
made for multiple comparisons.
Conclusion
The etiology of ICUAP with microbiologic confirmation
was polymicrobial in 16 % of patients. Pleural effusion and
absence of chronic heart disease are associated with poly-
microbial pneumonia. When empiric antibiotic treatment
is frequently appropriate, polymicrobial etiology does not
influence the outcome of ICUAP.
Key messages
 Polymicrobial etiology of ICU-acquired pneumonia
accounted for 16 % cases with microbiologic
confirmation
 Polymicrobial etiology of ICU-acquired pneumonia
was associated with pleural effusion and absence of
chronic heart disease
 Polymicrobial etiology did not result in higher
incidence of multi-drug- and extensive-drug-
resistant pathogens
 When empiric treatment is appropriate,
polymicrobial etiology does not influence the
outcome of ICU-acquired pneumonia
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